Potential roles of MNREAD acuity charts and contrast/glare sensitivity in Ranibizumab treatment of branch retinal vein occlusion.

Hirotaka Tanabe,Kiyomi Ichikumi,Akira Obana,Yuko Gohto,Takanobu Moriyama,Takahiko Seto,Sachiko Yamamoto,Alon Harris

doi:10.1371/journal.pone.0235897

Hirotaka Tanabe, Kiyomi Ichikumi + Show 6 more

Open Access

https://doi.org/10.1371/journal.pone.0235897

Copy DOI

Journal: PloS one	Publication Date: Jul 10, 2020
Citations: 5	License type: CC BY 4.0

Affiliation: Seirei Hamamatsu General Hospital

Abstract

Background/ObjectivesTo investigate the potential utility of MNREAD acuity charts and contrast/glare sensitivity (CGS) assessment for evaluating the efficacy of an initial treatment with ranibizumab (Lucentis®) for branch retinal vein occlusion (BRVO).MethodsIntravitreal injections of ranibizumab were administered in 43 eyes of 43 treatment-naïve patients with BRVO. Efficacy was assessed 1 month later. Best-corrected far/near visual acuity (BCFVA/BCNVA), MNREAD parameters (reading acuity [RA], maximum reading speed [MRS], critical print size [CPS]), CGS (CS/GS), and central macular thickness (CMT) in optical coherence tomography (OCT) before and after treatment were evaluated. The area (superior/inferior) affected by BRVO was determined by fluorescein angiography.ResultsAll parameters improved significantly following treatment (p < 0.05), and all MNREAD and CGS parameters were significantly correlated with BCVA in the treated eye before and after treatment (p < 0.01). The changes in BCFVA, BCNVA, MRS, and CS were significantly correlated with the amount of change in CMT (p < 0.007; r = 0.415, 0.528, -0.465, and -0.508, respectively). MRS exhibited a percentage change that was significantly correlated with that in CMT (p < 0.007; r = -0.511). Additionally, MRS exhibited the lowest threshold CMT (397 μm) at which the most significant change in improvement was observed. CMT was less likely to improve if BRVO occurred at a superior site than if it occurred at an inferior site (0.05 < p = 0.07 < 0.1).ConclusionsMNREAD and CGS testing were useful for evaluating BRVO treatment efficacy. MRS might be a valuable index for evaluating treatment success and making treatment decisions.

Highlights

Intravitreous injection of an anti-vascular endothelial growth factor (VEGF) agent is the current standard treatment for macular edema secondary to branch retinal vein occlusion (BRVO) [1,2,3,4,5]
The changes in BCFVA, BCNVA, maximum reading speed (MRS), and contrast sensitivity (CS) were significantly correlated with the amount of change in central macular thickness (CMT) (p < 0.007; r = 0.415, 0.528, -0.465, and -0.508, respectively)
CMT was less likely to improve if BRVO occurred at a superior site than if it occurred at an inferior site (0.05 < p = 0.07 < 0.1)

Summary

Introduction

Intravitreous injection of an anti-vascular endothelial growth factor (VEGF) agent is the current standard treatment for macular edema secondary to branch retinal vein occlusion (BRVO) [1,2,3,4,5]. In the PRN regimen, the change in macular edema evaluated by changes in retinal thickness and morphology by optical coherence tomography (OCT) and the change in visual acuity are the general criteria for determining treatment. Another important criterion is the degree of patient satisfaction. Patient satisfaction is not always consistent with the changes in OCT findings and visual acuity One reason for this discrepancy is that visual acuity is only one of several parameters related to visual function and does not fully represent the patient’s problem. The relationships among these and other parameters in naive BRVO patients who receive ranibizumab as an initial anti-VEGF treatment warrant investigation

Objectives

Methods

Results

Conclusion